Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN)
This research study is being done because we have not yet been able to find the best
treatment for recurrent or advanced head and neck cancer (SCCHN). Pemetrexed and
gemcitabine have helped fight against SCCHN when each was given by itself. This study is
different from others because it tests these two drugs together, which has not been tried
before in patients with SCCHN. We will see how well these drugs can work to help to control
or shrink your cancer.
We also want to find out what effects (good and bad) gemcitabine and pemetrexed have on you
and your head and neck cancer. We do not know if these drugs will help you. Your cancer
might get better or it might get worse. It might not have any effect on your condition. We
can use what we learn from this research study to help other people with the same cancer.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate will be measured.
after every 2 cycles of treatment
Ranee Mehra, MD
Fox Chase Cancer Center - Medical Oncology
United States: Institutional Review Board
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|